This is a preview and has not been published.

Investigation the role of Human Leukocyte Antigen-G in Iraqi patients with papillary thyroid carcinoma


  • Noor H. Aljanabi Department of Biotechnology, College of Science, University of Baghdad, Baghdad, Iraq.
  • Reema M. Abed Department of Biotechnology, College of Science, University of Baghdad, Baghdad, Iraq.



HLA-G, papillary thyroid cancer, preoperative diagnosis, risk factor, tumor marker


Human leukocyte antigen G (HLA-G) is a non-classical major histocompatibility complex (MHC) protein with well-known immunomodulatory characteristics. It is also believed to be an important sign of immune tolerance in cancer cells. Immune Escape. HLA-G is also associated with disease development and prognosis in cancer patients. The goal of this study was to compare soluble HLA-G (sHLA-G) levels before and after radioactive iodine therapy (RAI) by enzyme immunoassay (ELISA). Immunohistochemistry was used to examine HLA-G protein expression in thyroid tissues from patients with papillary thyroid cancer (PTC) to investigate the relationship between HLA-G expression and patients' clinical variables. Prospective research included 138 blood samples from patients and controls, as well as 25 thyroid paraffin-embedded tissues from individuals suffering from papillary thyroid cancer (PTC) and controls. Our findings demonstrated a significant difference in the means of people who had radioactive iodine therapy against those who did not (Mean SE = 4.19 0.31, 2.216 0.08, respectively). HLA-G staining, on the other hand, was identified in tumor cells in papillary thyroid cancer, all sections were positive, strongly stained and completely membranous, indicating the presence of HLA-G protein in the tested material. These findings suggest that HLA-G may be involved in the pathogenesis of papillary thyroid cancer.


Download data is not yet available.


Nunes LM, Ayres FM, Francescantonio IC, Saddi VA, Avelino MA, Alencar RD, et al. Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer. Hum Immunol. 2013;74 (4): 447-51.

Siraj AK, Parvathareddy SK, Qadri Z, Siddiqui K, Al-Sobhi SS, Al-Dayel F, et al. Annual hazard rate of recurrence in Middle Eastern papillary thyroid cancer over a long-term follow-up. Cancers. 2020; 12(12): 3624.

American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? Cancer. 2017; 123(3): 372-81.

Shih IM. Application of HLA-G expression in the diagnosis of human cancer. Hum Immunol 2007; 68(4): 272–6.

Rebmann, V, LeMaoult, J, Rouas-Freiss, N, Carosella ED, Grosse-Wilde H. Report of the wet workshop for quantification of soluble HLA-G in Essen. Hum Immunol. 2005; 66(8), 853-863.

Davies B, Hiby S, Gardner L, Loke YW, King A. HLA‐G expression by tumors. Am J Reprod Immunol. 2001; 45(2): 103-7.

Shams AA, Hamssa AJ. Relationship between rs1800796 Polymorphism of IL-6 Gene and IL-6 Serum Level with Thyroid Hormones in a Sample of Iraqi Celiac Disease Patients. Iraqi J Sci. 2022; 21(2).

Kaliszewski K, Diakowska D, Rzeszutko M, Rudnicki, J. Obesity and overweight are associated with minimal extrathyroidal extension, multifocality and bilaterality of papillary thyroid cancer. J Clin Med. 2021; 10 (5): 970.

Derwahl M, Nicula D. Estrogen and its role in thyroid cancer. Endocr. -Relat. Cancer. 2014; 21(5): T273-T283.

Cho YA, Kim J. Thyroid cancer risk and smoking status: a meta-analysis. Cancer Causes Control. 2014; 25, 1187-1195.

Kunzmann AT, Coleman HG, Huang WY, Berndt SI. The association of lifetime alcohol use with mortality and cancer risk in older adults: A cohort study. PLoS Med. 2018; 15(6): e1002585.

Mousa SA, Hercbergs A, Lin HY, Keating KA, Davis PJ. Actions of thyroid hormones on thyroid cancers. Front Endocrinol. 2021; 12: 691736.

Rummel SK, Ellsworth RE. The role of the blood ABO group in cancer. Future Sci. 2016; 2(2).

Ito N, Yokota M., Nagaike C, Morimura Y, Hatake K, Tanaka O, et al. Simultaneous expression of keratan sulphate epitope (a sulphated Poly-N-acetyllactosamine) and blood group ABH antigens in papillary carcinomas of the human thyroid gland. J Histochem. 1996; 28: 613-23.

Geneş D, Pekkolay Z, Şimşek M, Saraçoğlu H, Turgut M, Tuzcu AK. Importance and Risk Prediction of ABO Blood Group and Rh Factor in Papillary Thyroid Cancer. J Endocrinol. 2022; 4(1): 8-13.

Khoshsirat S, Peyvandi AA, Oroei M, Peyvandi H, Rezaeifard A. The Estimation of Thyroid Cancer Risk based on Type 2 Diabetes Mellitus and ABO Blood Group. Turk J Oncol. 2019; 35(1).

Crescenzi A, Taccogna S, Turrini L, Modica DC, Papini E, Gallo A, et al. Phenotypic changes of the thyrocyte membrane in papillary thyroid carcinoma. A three-dimensional study. J Endocrinol Invest. 2011; 34: e64-e69.

Berta E, Lengyel I, Halmi S, Zrínyi M, Erdei A, Harangi M. Hypertension in thyroid disorders. Front Endocrinol. 2019; 10: 482.

Sharma AK, Arya R, Mehta R, Sharma R. Hypothyroidism and cardiovascular disease: factors, mechanism and future perspectives. Curr Med Chem. 2013; 20(35): 4411-8.

Wu P. Thyroid disorders and diabetes. It is common for a person to be affected by both thyroid disease and diabetes. Diabetes Self Manag. 2007; 24(5): 80-7.

Siraj S, Masoodi T, Siraj AK, Azam S, Qadri Z, Parvathareddy SK, et al. APOBEC SBS13 Mutational Signature—A Novel Predictor of Radioactive Iodine Refractory Papillary Thyroid Carcinoma. Cancers. 2022; 14(6): 1584.

Marti JL, Morris LG, Ho AS. Selective use of radioactive iodine (RAI) in thyroid cancer: no longer “one size fits all”. Eur J Surg Oncol. 2018; 44(3): 348-56.

Davies B, Hiby S, Gardner L, Loke YW, King A. HLA-G expression by tumors. Am J Reprod Immunol 2001; 45: 103–7.

Mwafaq K, Abbas K, Abdullah H, Ghafour A. The Immunohistochemically Estimation of CD63 in Iraqi Patients with Gastric Cancer. Baghdad Sci. J..2022; 19(5),0932-0932.

Ismael, K. The prognostic value of some epithelial-mesenchymal transition markers and metastasis-related markers in human transitional cell carcinoma of the bladder. Baghdad Sci. J. 2018; 15(3), 0244-0244.